EGFR and colorectal cancer: Approximately 10% of colorectal cancers harbor native mutations in PTPRS, and inactivation of PTPRS promotes ERK and AKT activation, resulting in enhanced RAS and EGFR activity in colorectal cancer (Davis et al., 2018).